Calcium Antagonists

1. Front Matter

   Pages i-xxv

   PDF

2. Calcium Channels, The Molecular Approach

   1. Structure-Function Studies of the Voltage-Dependent Calcium Channels

      • Olga Krizanova, Philippe Lory, Arnold Schwartz

      Pages 1-8

   2. Regulation of Calcium Channels By Protein Phosphorylation

      • M. M. Hosey, R. M. Brawley, C. F. Chang, L. M. Gutierrez, J. Ma, E. Rios et al.

      Pages 9-14

   3. Interactions of Lacidipine and other Calcium Channel Drugs with Biological Membranes: A Structural Model for Receptor/Drug Binding Utilizing the Membrane Bilayer

      • Leo G. Herbette, Giovanni Gaviraghi, Robert J. Dring, Lawrence J. Briggs, R. Preston Mason

      Pages 15-23

3. Cardiovascular Applications of Calcium Antagonists: From Pathophysiology to Therapy

   1. Hypertension and Heart Failure

      1. Regulation of Calcium Channels in Vascular Smooth Muscle

         • Nicole Morel, Theophile Godfraind

         Pages 25-30

      2. Calcium and the Production of Endothelium-Derived Vasoactive Factors

         • V. B. Schini, T. Nagao, S. Illiano, P. M. Vanhoutte

         Pages 31-36

      3. Postnatal Development of Calcium Channels in Cardiac Muscle

         • M. Wibo, T. Godfraind

         Pages 37-42

      4. The Hemodynamic Effects of Calcium Antagonists under Pathological Conditions

         • P. A. van Zwieten

         Pages 43-48

      5. Calcium, Ischemia, and the Calcium Antagonists

         • Winifred G. Nayler

         Pages 49-58

      6. Multiple Organ Protection through Endothelial Cell Stabilization: A Mechanism of Action of Calcium Antagonists?

         • Fred De Clerck, Walter Janssens, Fons Verheyen

         Pages 59-63

      7. New Insight into the Vascular Properties of Lacidipine

         • G. Gaviraghi, T. Godfraind

         Pages 65-69

      8. Effect of Felodipine on Left Ventricular Performance in Conscious Dogs: Assessment by Left Ventricular Pressure-Volume Analysis

         • W. C. Little, C. P. Cheng

         Pages 71-76

      9. Lacidipine in the Treatment of Hypertension: Clinical Data

         • Giuseppe Mancia

         Pages 77-85

      10. Insights in the Cardioprotective Mechanism of the New Drug R56865

          • F. Verdonck, F. V. Bielen, L. Ver Donck, M. Borgers

          Pages 87-92

      11. Do the Differences Between Calcium Antagonists Matter When Treating Hypertension?

          • T. Morgan, A. Anderson

          Pages 93-98

      12. Effects of Lacidipine on Ischemic and Reperfused Myocardium

          • A. Boraso, A. Cargnoni, A. Maggi, R. Ferrari, O. Visioli

          Pages 99-106

   2. Atherosclerosis

      1. Atherogenic Activity caused by Excess Membrane Cholesterol in Arterial Smooth Muscle: Role of Calcium Channels

         • Thomas N. Tulenko, R. Preston Mason, Meng Chen, Hiromi Tasaki, Daniel Rock, David Stepp

         Pages 107-115

      2. Understanding the Initiating Factors in Atherosclerosis: Implications for Intervention

         • Winifred G. Nayler

         Pages 117-124

      3. Calcium Antagonists and Lipid-Lowering Agents in the Protection of the Arterial Wall

         • R. Paoletti, M. Raiteri, M. Soma, F. Bernini

         Pages 125-132

      4. Calcium Channel Blockers as Agents for the Treatment of Atherosclerosis

         • Philip D. Henry, Moises Bucay

         Pages 133-138

Although the importance of calcium (Ca²⁺) in the maintenance of cardiac contractility was recognized as early as 1880, the critical role of the ion in the contractile process in skeletal, cardiac, and smooth muscle has only been established within the last three decades.
As the complexity of the pharmacological actions of the Ca²⁺ channel inhibitors grows, there is a continued need to further clarify the inhibitors, both chemically and functionally.
This volume provides an update of the field based on the work presented at the 5th International Symposium on Calcium Antagonists: Pharmacology and Clinical Research. It reviews the current state of the growing area of molecular biology of Ca²⁺ channels. In the cardiovascular area, in addition to the well-established clinical uses of Ca²⁺ channel inhibitors, exciting new work pointing to an application in atherosclerosis is described. The book also includes important uses of Ca²⁺ antagonists in novel areas of interest such as the gastrointestinal tract, renal protection and multi-drug resistance.

• atherosclerosis
• calcium
• cardiovascular
• clinical research
• drug resistance
• heart
• hypertension
• pathophysiology
• physiology
• research
• resistance

• Laboratory of Pharmacology, Catholic University of Louvain, Brussels, Belgium

  T. Godfraind

• Institute of Pharmacological Sciences, University of Milan, Milan, Italy

  R. Paoletti, S. Govoni

• Center for Experimental Therapeutics, Baylor Institute of Medicine, Houston, USA

  P. M. Vanhoutte

Policies and ethics